Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiotoxicity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    60 result(s) found for: Cardiotoxicity. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-001707-11 Sponsor Protocol Number: M06HER Start Date*: 2007-06-07
    Sponsor Name:NKI-AvL
    Full Title: Prospective, randomized, pharmacological intervention study; evaluating the effect of the angiotensin II-receptor (AT1) blocker candesartan versus placebo in prevention of trastuzumab-associated ca...
    Medical condition: WHO: 0-2 Serum creatinine <140 umol/l Thyroid stimulating hormone between 0.5-3.9 MU/l. Blood pressure systolic ≥ 140 mmHg diastolic ≥ 90 mmHg is acceptable at randomization. LVEF  50% assessed b...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001467-20 Sponsor Protocol Number: COBC Start Date*: 2017-08-19
    Sponsor Name:Dept. of Oncology, Karolinska university hospital
    Full Title: Effects of Identifying and Treating Early, Subclinical Cardiotoxicity on the Long- Term Incidence of Clinical Cardiotoxicity in Women with Breast Cancer, a prospective randomised study: The Cardio-...
    Medical condition: Women with newly diagnosed breast cancer who are expected to receive neo-adjuvant or adjuvant therapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020806 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001094-16 Sponsor Protocol Number: PROACT Start Date*: 2017-08-08
    Sponsor Name:South Tees NHS Foundation Trust
    Full Title: Preventing cardiac damage in patients treated for breast cancer and lymphoma: a phase 3 Randomised, Open label, blinded endpoint, trial of enalapril to prevent Anthracycline-induced CardioToxicity ...
    Medical condition: Prevention of cardiotoxicity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10048610 Cardiotoxicity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-002207-15 Sponsor Protocol Number: Cardiorete Start Date*: 2011-12-27
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO
    Full Title: A prospective study with beta-blockers and ACE-inhibitors in patients operable breast cancer experiencing mild cardiac toxicity during treatment with anthracycline and/or trastuzumab
    Medical condition: patients experiencing mild cardiotoxicity during treatment with anthracycline and/or trastuzumab for operable breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002248-26 Sponsor Protocol Number: IEOS701/412 Start Date*: 2012-10-16
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Prevention of anthracycline-induced cardiotoxicity: a multicentre randomizedtrial comparing two therapeutic strategies.
    Medical condition: Anthracycline-­‐induced cardiotoxicity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10008444 Chemotherapy cardiotoxicity attenuation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004618-24 Sponsor Protocol Number: 012018CONTROL Start Date*: 2018-08-03
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: Evaluation of CardioprOtection by the use of betablocker Nebivolol in paTients with bReast cancer Or diffuse Large B cell lymphoma undergoing chemotherapy with anthracyclines: a randomized controll...
    Medical condition: To prevent cardiotoxicity of chemotherapeutic agents (anthracyclines)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10042613 - Surgical and medical procedures 10008444 Chemotherapy cardiotoxicity attenuation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000914-23 Sponsor Protocol Number: SAFE2014 Start Date*: 2016-08-05
    Sponsor Name:DIPARTIMENTO DI SCIENZE BIOMEDICHE SPERIMENTALI E CLINICHE, UNIVERSITà DI FIRENZE
    Full Title: Cardiac toxicity prevention in non-metastatic breast cancer patients treated with anthracycline-based chemotherapy: a randomized, placebo controlled, phase 3 trial - SAFE trial.
    Medical condition: Female, non metastatic histologically confirmed primary invasive breast cancer scheduled to receive neoadjuvant or adjuvant anthracyclines with or without anti Her 2 therapy, LVEF >50%
    Disease: Version SOC Term Classification Code Term Level
    20.1 10042613 - Surgical and medical procedures 10008444 Chemotherapy cardiotoxicity attenuation PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002270-12 Sponsor Protocol Number: TRIMETA Start Date*: 2016-10-20
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Clinical trial phase II, prospective, open, randomized, controlled study to evaluate the preventive effect of trimetazidine on the cardiotoxicity of trastuzumab and chemotherapy in patients with br...
    Medical condition: BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003470-10 Sponsor Protocol Number: 2206-2006 Start Date*: 2007-05-22
    Sponsor Name:Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
    Full Title: Randomised Phase II study with non-pegylated liposomal Doxorubicin (Myocet) plus Ifosfamid versus Doxorubicin plus Ifosfamid in the first-line treatment of locally advanced or metastatic soft tissu...
    Medical condition: Patients with locally advanced or metastatic soft tissue carcinoma and without any prior treatment are eligible for this study.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000661-20 Sponsor Protocol Number: ICO Start Date*: 2019-05-31
    Sponsor Name:Vilnius University Hospital Santaros klinikos
    Full Title: Ivabradine to prevent anthracycline-induced cardiotoxicity: a prospective randomized open label clinical trial.
    Medical condition: Cancers treated with anthracyclines: leukemias, limphomas, breast, stomach, uterine, ovarian, lung.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002004-42 Sponsor Protocol Number: OPHA 05-55 Start Date*: 2005-09-23
    Sponsor Name:Grupo Oncopaz y Hospitales Asociados
    Full Title: "Phase IV-II safety protocol, open-label , not randomized, of Myocet® in combination with Taxotere® as first line antineoplasic treatment in patients with advanced breast cancer”Protocolo de trata...
    Medical condition: Advanced Breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001065-17 Sponsor Protocol Number: GEL-R-COMP-2013 Start Date*: 2013-08-01
    Sponsor Name:Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL/TAMO)
    Full Title: Phase II, randomised, multicentre study with two treatment arms (R-COMP versus R-CHOP) in newly diagnosed elderly patients (?60 years) with non-localised diffuse large B-cell lymphoma (DLBCL)/folli...
    Medical condition: Non-localised diffuse large B-cell lymphoma/Follicular lymphoma grade IIIb
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-001257-31 Sponsor Protocol Number: TACTIDA Start Date*: 2021-08-25
    Sponsor Name:Department of Pharmaceutical Biosciences, Uppsala University
    Full Title: An open, single center two-step trial (A+B), comparing the safety and tolerability of idarubicin 10 mg and 15 mg after separate single hepatic intra-arterial injections of a drug formulation based ...
    Medical condition: intermediate stage hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000251-18 Sponsor Protocol Number: PO4572 Start Date*: 2006-05-12
    Sponsor Name:Dr. Llombart Cussac
    Full Title: Phase II Cardiac Safety trial of liposomal pegillated doxorrubicine in patients with breast cancer with non evidence of disease and previous exposition to Antraciclines. Estudio Fase II de Seguri...
    Medical condition: Non evidence of disease (NED) Breast cancer.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003466-18 Sponsor Protocol Number: DECT Start Date*: 2009-01-15
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: PHASE II TRIAL OF PRIMARY CHEMOTHERAPY WITH TRASTUZUMAB IN COMBINATION WITH DOCETAXEL FOLLOWED BY EPIRUBICIN-CYCLOPHOSPHAMIDE IN PATIENTS WITH HER2-OVEREXPRESSING OPERABLE BREAST CANCER
    Medical condition: Primary chemotherapy in Her2-overexpressing operable breast cancer patient
    Disease: Version SOC Term Classification Code Term Level
    6.1 10057654 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000617-19 Sponsor Protocol Number: DOXIL-BCA-3001 Start Date*: 2004-09-13
    Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development
    Full Title: A Randomized Controlled Study of Docetaxel Monotherapy or Docetaxel and DOXIL for the Treatment of Advanced Breast Cancer
    Medical condition: Breast cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) AT (Completed) ES (Completed) GB (Completed) DE (Completed) LT (Completed) LV (Completed) EE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001201-24 Sponsor Protocol Number: SOLTI-1002 Start Date*: 2012-12-05
    Sponsor Name:SOLTI
    Full Title: A prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin (Myocet®) plus paclitaxel, trastuzumab, and pertuzumab in patients with operable...
    Medical condition: HER2-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-005282-12 Sponsor Protocol Number: Start Date*: 2013-05-14
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. Research and Development NHS Lothian
    Full Title: TOFFEE Trial Toxicity OF Fluoropyrimidines: A comparative study of the cardiotoxicity of capEcitabine and tEysuno
    Medical condition: All gastrointestinal and hepatobiliary cancers including colorectal cancer, cancer of unknown primary, pancreatic cancer, stomach cancer and oesophageal cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016930-29 Sponsor Protocol Number: MeIn/09/Ran-Car/01 Start Date*: 2010-04-15
    Sponsor Name:MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.
    Full Title: Ranolazine to treat early cardiotoxicity induced by antitumor drugs
    Medical condition: Patients who completed standard dose chemotherapy for the treatment of non-Hodgkin lymphoma or the adjuvant treatment of breast cancer or colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025322 HLGT
    9.1 10006200 PT
    9.1 10009944 PT
    9.1 10038038 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003844-41 Sponsor Protocol Number: 2719 Start Date*: 2007-03-02
    Sponsor Name:Royal Marsden NHS Trust
    Full Title: Feasibility study of R-CHOP plus bevacizumab in patients with diffuse large B cell lymphoma (DLBCL)
    Medical condition: Previously untreated diffuse large B-cell non-Hodgkin's lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:20:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA